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Extracellular vesicles (EVs), including microvesicles (MVs) and exosomes, are small vesicles
secreted from a wide variety of cells. Whereas MVs are particles released by the outward
budding of the plasma membrane, exosomes are derived from endocytic compartments.
Secretion of EVs can be enhanced by specific stimuli, and increased plasma circulating lev-
els of EVs have been correlated with pathophysiological situations. MVs, already present in
the blood of healthy individuals, are considerably elevated in several cardiovascular diseases
associated with inflammation, suggesting that they can mediate deleterious effects such
as endothelial dysfunction or thrombosis. Nonetheless, very recent studies also demon-
strate that MVs may act as biological information vectors transferring proteins or genetic
material to maintain cell homeostasis, favor cell repair, or even promote angiogenesis. Addi-
tionally, exosomes have also been shown to have pro-angiogenic and cardio-protective
properties. These beneficial effects, therefore, reveal the potential therapeutical use of
EVs in the field of cardiovascular medicine and regenerative therapy. In this review, we
will provide an update of cellular processes modulated by EVs of specific interest in the
treatment of cardiovascular pathologies. A special focus will be made on the morphogen
sonic hedgehog (Shh) associated with EVs (EVsShh+), which have been shown to mediate
many pro-angiogenic effects. In addition to offer a potential source of cardiovascular mark-
ers, therapeutical potential of EVs reveal exciting opportunities to deliver specific agents
by non-immunogenic means to cardiovascular system.
Keywords: extracellular vesicle, microparticles, microvesicles, exosomes, cardiovascular diseases, angiogenesis,
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INTRODUCTION
Extracellular vesicles (EVs) comprising exosomes (<100 nm of
size), microparticles, and apoptotic bodies (100–1200 nm in size)
are physiologically released by almost all cell types and repre-
sent endogenous cargos that are able to participate in cell-to-cell
communication. The composition of EVs determines the type of
message, which they can convey. Indeed, EVs are rich in proteins,
mRNAs, and miRNAs as well as lipids, which they can transfer to
target cells by ligand/receptor interaction, fusion, and/or internal-
ization. Manipulation of cells generating EVs by pharmacological
treatment or transfection allow to produce EVs rich in specific
components that can affect selectively the functions of target cells.
In this article, we will review the current knowledge of the function
and impact of EVs used as therapeutic tools against cardiovascular
diseases.
EVs: POTENTIAL DELIVERY TOOLS/VECTORS IN THE
CARDIOVASCULAR SYSTEM
In addition to their different size, the criteria that are used to dis-
tinguish between the various types of EVs are based on the cellular
compartment that they originate from and on their composition
(1). While exosomes are formed from the multivesicular bod-
ies, both microparticles and apoptotic bodies come from plasma
membrane. Obviously, composition of EVs depends on the type of
(i) cells that they are from and (ii) stimulation that generates their
release. Thereby, specific antigens carried by EVs allow the iden-
tification of donor/producer cell, whereas use of different agents
to stimulate EV generation allows achieving EVs with different
potential effects.
Extracellular vesicles have been isolated from the main fluids
of the organism and from several solid tissues (tumors, atheroma
plaque, skeletal muscle. . .). However, it is difficult to establish the
exact nature of EVs from solid tissues, as the recovered mate-
rials can also comprise intracellular vesicles released during the
tissue dissociation process (2). In addition to their physiological
role during development and homeostasis, some pathophysiolog-
ical situations will enhance release of EVs and affect composition
of EVs or both. Thus, during cardiovascular diseases, both ele-
vated levels and different composition of EVs have been described
suggesting that EVs may represent potential novel targets for ther-
apeutic intervention (3, 4). Of note, circulating endothelial EVs
were associated with the presence of cardiometabolic risk factors
in a community cohort underscoring the potential influence of
high-risk metabolic profiles on endothelium activation or injury
(5). Given the fact that elevated EV levels often correlate with
the severity of cardiovascular diseases, one strategy would consist
in reducing circulating EVs to normal levels in order to prevent
associated deleterious signaling. In this perspective, many ongoing
studies are designed to evaluate changes in circulating EV levels
in response to pharmacological treatment used [for review, see
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Ref. (6)]. However, such strategies do not allow distinguishing
between effects of drugs on EV generation and/or EV clearance.
An alternative to modulate EV production would be either to act
on processes regulating their formation and/or release or to inhibit
their interaction with target cells through specific targeting of their
components (receptors, ligands, lipids. . .) (7). Notably, inhibition
of ceramide formation by the use of amiloride drug reduces signif-
icantly mouse and human tumor cell growth by blocking secretion
of heat shock protein-72 (HSP 72) EV-associated protein (8).
While no studies using such strategies have been yet described
in cardiovascular field, a limiting step is also linked to the lack of
specificity of targeting mechanisms regulating EV formation and
release, which may produce many unwanted effects.
Alternatively, EVs constitute promising therapeutic delivery
tools in cardiovascular diseases. Their general capacity to act as
bioactive cargoes, particularly through their ability to carry secre-
tory molecules such as cytokines, chemokines, or growth factors
as well as exogenous nucleic acids, highlight them as attractive
vehicles (9). In addition, EVs are able to use the vasculature to
signal at considerable distance from their donor cell origin. In this
respect, central nervous system-derived EVs could enter the blood-
stream and communicate with endothelial cells in the peripheral
circulation and with cells involved in immune surveillance (10).
Although largely identified as deleterious carriers, EVs might
also have beneficial effects and deliver protective messages to
preserve endothelial function and/or vascular integrity. Indeed,
circulating EVs from sepsis patients are able to restore vascu-
lar hyporeactivity in vessels treated by lipopolysaccharide (11).
In agreement, high circulating levels of EVs correlate with sur-
vival in sepsis patients (12). Besides this EV-mediated adap-
tative/protective response, EVs have demonstrated regenerative
capacities, mainly when they derived from progenitor or mes-
enchymal stem cells (MSC), therefore, opening perspectives to use
their innate properties in regenerative medicine (Figure 1).
THERAPEUTIC USE OF MSC-DERIVED EVs IN CARDIAC
REGENERATIVE MEDICINE
Cardiac regenerative therapy, based on intramyocardial injec-
tion of MSCs, has been in the last few years one of the most
promising approaches to both prevent cardiac damage and allow
FIGURE 1 |Therapeutical potential of extracellular vesicles in the
context of cardiovascular disorders. Extracellular vesicles (EVs)
constitute bioactive cargoes, particularly through their ability to carry
proteins, receptors but also genetic material including microRNA (miRNA)
or mRNA. Since EVs participate actively in the modulation of many
physiological processes, they can be used as therapeutic agents in
cardiac regenerative medicine. Improvement of cardiac function depends
on the EV-transfer of specific factors, such as soluble proteins, growth
factors, lipids, or genetic material. Use of stem cell-derived EVs in cardiac
regenerative therapies, therefore, allows delivering specific signals by
non-immunogenic means to heart. As EVs naturally contain genetic
material, cell sources can be genetically manipulated to produce EVs
specifically loaded with miRNA of choice, such as miR-150 or miR-126,
described as important regulators of angiogenesis or vascular integrity.
Treatment of endothelial cells or vascular tissues with these
miRNA-enriched EVs has demonstrated their protective and regenerative
properties on cardiovascular system. Specific culture system might also
allow to specifically targeting molecules of interest to EVs, like the
morphogen Shh that is an important regulator of injury-induced
angiogenesis and neovascularization. Use of EVsShh+ even appears in this
context more powerful than classical recombinant Shh protein, likely
linked to its localization within natural EV membranous environment.
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cardiac repair. However, experimental or clinical studies demon-
strate insufficient cardiomyocyte or vascular cell differentiation
to account for improvements of cardiac function (13). This led
to formulate the paracrine-hypothesis according to which sol-
uble factors derived from MSCs would be responsible for ben-
eficial outcomes (14, 15). First evidences establishing that cel-
lular secretions are cardio-protective resulted from administra-
tion of MSC-derived conditioned medium to rodents and pigs,
which results in reduced infarct size and led to improved heart
function (16–18). Also, exosomal fraction contained in MSC-
conditioned medium mediates preservation of cardiac function
after ischemia/reperfusion injury (19). These protective effects
likely result from decreased oxidative stress and activation of
PI3K/Akt pathway, which enhance myocardial viability and pre-
vent adverse cardiac remodeling (20). Of note, EVs derived from
bone marrow CD34+ stem cells or endothelial progenitor cells
(EPCs) have been shown to promote angiogenesis (21, 22).
Of great interest is the recently reported potential of EVs, par-
ticularly exosomes, derived from cardiac progenitor cells (CPC).
Indeed, CPC-derived EVs have been shown to stimulate migra-
tion of endothelial cells (23) and to protect ischemic myocardium
from acute ischemia/reperfusion injury (24). This would, there-
fore, open new perspectives to directly used EVs derived from
cells present in the heart itself. Accordingly, electron microscopic
imaging of CPCs and adult mouse hearts has revealed the release
of vesicles, which would have the morphological characteristics
of EVs (25).
Altogether, the use of stem cell-derived EVs instead of stem
cells engraftment might open new perspectives for cardiac regen-
erative therapies. This would first resolve safety concerns related
to uncontrolled dissemination of transplanted cells or aberrant
stem cell differentiation. In addition, immunosuppressive effects
reported for certain EVs could favor efficient cardiac tissue regen-
eration (26). Moreover, since exosomes could be easily stored and
keep their biological properties over an extended storage period,
they can overcome many of the limitations linked to the use of
viable cells in regenerative medicine. However, further investiga-
tions would be needed to optimize their characterization, quality,
and purification in order to accurately control their production
in the perspective of clinical uses (27). In particular, pro or anti-
tumor effects reported for MSC-derived EVs would need to be
fully understood and highly regulated (28, 29).
EVs AS GENE-THERAPY DEVICES
As described above,EV composition and cargoes transported (pro-
teins, genetic material, lipids) vary with cell origin. In addition to
use them as delivery vector for specific proteins, their ability to
transport and deliver genetic material to non-adjacent cells have
highlighted their potential as new delivery vectors in gene-therapy
(see Figure 1).
Extracellular vesicles derived from stem cells are reported as car-
riers for nucleic acids, which by horizontal transfer of mRNAs are
able to reprogram hematopoietic progenitors (30). Subsequently,
EPCs are also shown to activate angiogenesis in endothelial cells
by shuttling specific mRNA-derived EVs associated with the phos-
phoinositide 3-kinase (PI3K)/AKT signaling pathway, therefore,
inducing angiogenic responses (31).
Further investigations have demonstrated that delivery of
mRNAs was not restricted to MVs but could be extended to exo-
somes derived from mast cells (32) and could be translated once
after entering another cell (32–34). Furthermore, detailed RNA
analysis of total RNAs derived from EVs from various cell types
also revealed the presence of small RNAs, including microRNAs
(miRNA) (32, 35, 36). Transfer of miRNAs contained in exo-
somes derived from dendritic cells operates via fusion of cells,
leading to the release of the exosomes content into the dendritic
cell cytosol (37).
Numerous clinical studies have revealed that cardiovascular
diseases correspond with specific signature patterns of miRNA
expression (38, 39). Circulating EVs represent transport vehicles
for large numbers of specific miRNAs involved in fundamental
cellular processes related to cardiovascular disorders (40). Impor-
tantly, the comparison of ratio of miRNA expression in circulating
EVs to that in EV-free plasma reveals the majority of circulating
miRNAs were present in EVs (41). Since miRNA profile in EVs is
significantly different from their maternal cells, an active mech-
anism of selective “packaging” from cells into EVs likely occurs.
Of note, molecular packaging of miRNA-loaded exosomes is con-
trolled through the recognition of sequence motifs present in miR-
NAs by sumoylated protein hnRNPA2B1 (heterogeneous nuclear
ribonucleoprotein A2B1) (42). Moreover, this compartmentaliza-
tion may be regulated by external stimuli as illustrated by hypoxia,
which can modulate immunomodulatory and regenerative prop-
erties of MSC-derived EVs (16) but also enhanced expression of
pro-angiogenic miRNAs in EPC-derived EVs (43).
MiRNAs contained in EVs might efficiently regulate target
genes in recipient cells as illustrated with monocyte miRNA-
150, selectively packaged into EVs following treatments of human
monocyte/macrophage THP1 cells with inflammatory factors
(41). By the use of THP-1-derived EVs expressing a mimic miR-
150, the authors showed elevated miR-150 levels in in vitro EV-
treated endothelial cells as well as in mouse blood vessels following
EV intravenous injection. Consequently, protein level of c-Myb,
a gene targeted by miR-150, is effectively reduced resulting in
enhanced endothelial cell migration. This monocyte/macrophage
EVs delivery system has been further optimized by transfecting
donor cells with a chemically modified miRNA (miR-143), which
revealed higher stability (44).
MiR-126, an important regulator of angiogenesis and vascu-
lar integrity (45, 46) is enriched in different types of EVs, such
as apoptotic bodies derived from endothelial cells (47), endothe-
lial microparticles (48), or even EPCs (49). In agreement with the
striking evidence describing the role of miR-126 in the regulation
of vascular integrity on the molecular level, treatment with these
different types of miR-126-enriched EVs all promote vascular
regeneration. Indeed, systemic treatment of hypercholesterolemic
ApoE-/- mice with miR-126-enriched EVs limited atherosclero-
sis and increased Sca1+ cell incorporation into aortic plaques
(47) whereas miR-126-associated EVs promote reendothelializa-
tion in vivo (48). Alternatively, both angiogenic miR-126 and
miR-296 participate in the improvement of neovascularization
observed in a model of hindlimb ischemia induced in SCID mice
following treatment with EPC-derived EVs (49). Of particular
interest, miRNA profiling in patients with coronary artery disease
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has shown significantly reduced levels of miR-126 in comparison
with healthy controls (50) or even total loss circulating miR-126
in patients with diabetes mellitus (39). Therefore, development of
EV-based miR-126 therapeutic strategy might be promising in the
context of metabolic and cardiovascular diseases.
Our group has developed one type of EVs carrying the mor-
phogen Shh that reveals protective properties on cardiovascular
cells. The next part of this review is focused on the description of
the effects of these EVs.
EVs HARBORING Shh AS VASCULAR AND
CARDIO-PROTECTIVE DELIVERY TOOLS
IMPORTANCE OF Shh SIGNALING IN VASCULAR FUNCTION
Shh is a morphogen that belongs to the conserved hedgehog (Hh)
protein family. Hedgehog signaling is essential in vertebrates for
embryo patterning, as it participates in central nervous system
development, lateral asymmetry, and anterior–posterior limb axis
(51). In adult tissues, Shh signaling has been implicated in cell
proliferation, differentiation, and survival in a wide variety of tar-
get tissues/organs [reviewed in detail in Ref. (52)]. Hh proteins
are covalently linked to cholesterol at its carboxyl terminus (53)
and palmitoylated at its amino terminus (54). Both lipid modifi-
cations influence activities of Shh (55, 56) and long-range spread
of Shh signaling (57, 58). Diffusion of dual-lipid modified Shh
proteins apparently occurs via secretion as mono or large sol-
uble multimers, further transported via lipoproteins (59) or in
EVs (60–62). A major component of the Hh pathway includes
the 12 transmembrane receptor PTC (Patched) that constitutively
represses Hh signaling. Binding of Shh to PTC inhibits the repres-
sion of Smoothened (SMO), which functions as G protein-coupled
receptor (GPCR). This derepression leads to the activation of zinc-
fingers transcriptions factors Gli, which translocate to the nucleus
where they act as activators or repressors of target gene tran-
scription. Besides this classical-Shh signaling pathway, referred as
“canonical pathway,” other non-canonical pathways that do not
clearly act via the Shh-Smo-Gli axis have been reported, which
regulate many cellular processes including cell energy metabolism
(63, 64).
Shh signaling is crucial in new vessel formation during embryo-
genesis and organogenesis. Its role in angiogenesis and neovas-
cularization has been previously reviewed in details (65). Hh
signaling components are present in adult cardiovascular tissues
and can be activated in vivo (66). In adult tissue, activation of Shh
signaling, via recombinant Shh or gene-therapy transfer, triggers
cellular responses in a wide variety of vascular cells (endothelial,
EPCs, smooth muscle cells, fibroblasts) promoting angiogenesis
and protecting against ischemic injuries (66–68). These Shh effects
on cardiovascular system seem to operate via complex pathways,
involving Gli-dependent and independent pathways (Figure 2A).
Endothelial cells were initially considered not to respond to
recombinant Shh directly, but rather to rely on adjacent mesenchy-
mal cells thought to translate the presence of Hh ligand in signaling
molecules that act on the endothelium (66). Particularly, activation
of Shh signaling in intersticial mesenchymal cells enhances PTC,
VEGF (Vascular Endothelial Growth Factor), and angiopoietin-
1 and -2 protein expressions (66). Further studies demonstrate
that endothelial cells do respond to Hh inducing pro-angiogenic
responses (69, 70). PI3K/Akt and SMO dependencies have been
demonstrated to be essential for Shh signaling (71, 72). In agree-
ment, Shh acutely stimulates fibroblast migration and endothelial
cell tubulogenesis through Rho GTPases Rac1 and RhoA activation
depending on SMO-G(i)-coupling and PI3K,but independently of
Gli transcription factors (69, 73). Similarly, Shh promotes capillary
morphogenesis and endothelial cell migration via a RhoA/ROCK
dependent pathway, ultimately leading to increased expression of
metalloproteinase 9 (MMP-9) or osteopontin downstream targets
(74). Despite Gli nucleus translocation following Shh treatment
of endothelial cells, role of these transcription factors in Shh-
angiogenesis responses is not fully understood (71). Controversy
regarding Shh signaling is also present in vivo since Shh-induced
angiogenesis is not affected in Gli1 null-mice (74), whereas capil-
laries morphogenesis is inhibited by the presence of Gli1 inhibitor
GANT61 (70). Impaired angiogenesis in ischemic tissue of middle-
aged or old mice is associated with a decrease in Gli1 transcription
factor mRNA expression (68, 75). These results reflect the complex
interplay between canonical and non-canonical Shh pathways,
or at least that of the Gli family of transcription factors, in the
regulation of tubulogenesis and angiogenesis processes.
EVs HARBORING Shh AS PROMISING THERAPEUTICAL DEVICES FOR
CORRECTING ANGIOGENIC DEFECTS
Shh beneficial effects in angiogenesis reveal therapeutic poten-
tial for stimulating neovascularization in disease states associated
with impaired angiogenesis. This has led our group to engineer
EVs specifically enriched in this morphogen and derived from
activated T-lymphocytic cells. EVsShh+ are specifically retrieved
from conditioned medium when lymphocytes are treated with a
proactive stimulation, phytohemagglutin, and phorbol ester, fol-
lowed by a pro-apoptotic treatment with actinomycin D (62).
These EVsShh+ are functionally active and induce differentiation
of megakaryocytes. EVsShh+ downstream effects likely depend on
SMO activation, probably acting through direct Shh-PTC interac-
tion (see Figure 2B). In vitro capillary formation by umbilical vein
endothelial cells is both dependent on EVsShh+ concentration and
inhibited in presence of cyclopamine, which stabilizes SMO in an
inactive form (76). However, whether EVsShh+ induce activation
of Gli1 remain to be determined. In vitro, EVsShh+ increase mRNA
levels of several pro-angiogenic factors, such as VEGF, angiopoi-
etins, hepatocyte growth factor (HGF), interleukin-1β, MMP-1
and decrease anti-angiogenic factors such as transforming growth
factor β (TGF β) (76). EVsShh+ also increase cell adhesion and
induce formation of stress fibers of in vitro endothelial cells in
a SMO and Rho kinase pathways-dependent manner (76), likely
signaling through the same pathway as described for recombinant
Shh (69).
Angiogenic properties of EVsShh+ have been illustrated fol-
lowing their in vivo intravenous injection in mouse models (77).
In vivo injection of EVsShh+ in mice is able to improve endothe-
lial function by increasing nitric oxide (NO) release and reversing
endothelial dysfunction after ischemia/reperfusion (78). Indeed,
EVsShh+ trigger changes in the expression and phosphorylation
of enzymes related to NO pathway, which seem to be dependent
of the activation of kinases such as PI3K and ERK. Further-
more, 21 day-treatment of a model of mouse hind limb ischemia
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FIGURE 2 | Comparison between recombinant Shh- and
EVsShh+-activated pathways modulating angiogenesis and apoptosis in
endothelial cells. (A) Recombinant Shh protein was shown to promote
migration and capillary formation through SMO-Gi coupled and PI3K
activation, triggering ROCK pathway activation, and downstream targets
(MMP-9 and osteopontin). Such activation illustrates the importance of
non-canonical pathways in Shh-induced angiogenesis processes. Despite Shh
induction of Gli nuclear translocation in endothelial cells, role of canonical
signaling on vascular function remains elusive. Finally, activation of Hh
signaling counteracts non-canonical PTC-induced caspase-3 cleavage and
protects endothelial cells against apoptosis. (B) EVsShh+ were demonstrated
to use similar pathways than those described for recombinant Shh protein.
They additionally induce functional and mature blood vessel formation by
enhancing mRNA expression of several pro-angiogenic factors, especially
VEGF and decreasing mRNA of anti-angiogenic TGFβ. EVsShh+ also exert
vasculoprotective effects by inducing anti-oxidants defenses, particularly
through direct transfer of antioxidant enzymes (SOD, catalase) concurring to
decrease ROS intracellular levels. SMO, smoothened; PI3K,
phosphoinositide-3-kinase; ROCK, Rho-associated protein kinase; MMP-9,
matrix metalloproteinase-9; Hh, Hedgehog; PTC, Patched; VEGF, vascular
endothelial growth factor; TGFβ, transforming growth factor β; SOD,
superoxide dismutase; ROS, reactive oxygen species.
with EVsShh+ increase eNOS activation both in aorta and mus-
cle as well as several pro-angiogenic factors (77). Taken together,
lymphocytic-derived EVsShh+ are able to induce functional and
mature blood vessel formation by reciprocally regulating the pro-
and anti-angiogenic factors.
Apart from directly stimulating angiogenesis processes,
EVsShh+ reveal anti-apoptotic properties notably by decreasing
reactive oxygen species (ROS) production (78). Mechanistically,
EVsShh+ exert their vasculoprotective effects by promoting inter-
nalization and induction of antioxidant messages to the endothe-
lial monolayer. Indeed, EVsShh+ prevent apoptosis in endothelial
cells induced by actinomycin D by transferring functional antiox-
idant enzymes [superoxide dismutase (SOD) isoforms and cata-
lase] and by inducing cellular Mn-SOD protein expression (79).
Anti-apoptotic effects have also been reported following Hh ligand
treatment of endothelial cells, but rather relying on the inhibition
of the pro-apoptotic effect of PTC, normally leading to caspase-3
cleavage (69).
Therefore, EVsShh+ may represent a powerful tool in diseases
associated with failed angiogenesis, associated with their pro-
angiogenic and anti-apoptotic properties. In addition to observed
differences in regulated pathways, structural features of Shh asso-
ciated with EVs might be of particular importance. EVs provide
a lipidic environment analogous to cell membrane, which could
influence Shh downstream signaling considering the importance
of these lipid-adducts in Shh activity (57, 58). Finally, EV-delivery
of Shh protein seems to represent a major mechanism in the
observed preservation of cardiac function in stem cell-based ther-
apies. Indeed, CD34+ cells genetically modified to express Shh
[CD34+(Shh)] offer a better protection against ventricular dila-
tion and cardiac functional decline than CD34+ cells alone when
injected into mice after acute myocardial infarction (80). In vitro
analysis of exosomes derived from CD34+(Shh) further revealed
the functional transfer and activation of Shh signaling in recipient
cells, which might explain the observed preservation of cardiac
function in mice treated with CD34+ (Shh) EVs.
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Thus, EVs harboring Shh represent an exciting tool for
therapy regarding angiogenesis defects related diseases and
cardioprotection.
TOWARD CLINICAL TRANSLATION
Extracellular vesicles might be further used as delivery devices for
any molecule of interest. In particular, using naturally occurring
secreted vesicles might allow overcoming toxicity or immuno-
genicity associated with other developed carrying agents like lipo-
somes or nanoparticles. Moreover, this new drug-delivery system
might be combined with other existing therapeutic strategies to
optimize drug-delivery. Indeed, a recent report demonstrates that
adeno-associated viruses (AAVs) are more efficient when encap-
sulated in EVs (termed vexosomes) than free AAVs for the delivery
of cargo into recipient cells. Such a unique entity offers a promis-
ing strategy to improve gene delivery (81). Alternatively, tumor
cells incubated with chemotherapeutic drugs are able to package
these drugs into EVs, which can be collected and used to effec-
tively kill tumor cells in murine tumor models without typical
side effects (82).
Furthermore, the use of biological material as carriers might
also allow getting molecules in their native conformation, due
to natural interaction or folding with membranous environment.
Different strategies might be used to specifically target molecules
in EVs. For example, addition of different types of membrane
anchors can target highly oligomeric cytoplasmic proteins to sites
of vesicle secretion and EVs (83). Another important issue is
the biodistribution of EVs. Indeed, EVs are circulating through
many fluids, and have been especially recovered from blood or
lymph, therefore allowing their large dissemination in the organ-
ism. Such circulating properties are of particular interest in the
treatment of cardiovascular alterations since the entire vascular
network would be exposed to EVs. Since dissemination or accumu-
lation of these biological vectors may also be hindered, one could
need to specifically target cargo delivery to enhance EV properties.
Elegant studies using engineering donor cells expressing peptide
targeting-ligand subsequently recovered in EVs produced by cells
have respectively allowed to specifically target neurons (84) and
breast cancer cells (85).
Despite interesting perspectives for cardiovascular treatment,
EV-based therapies still need more investigations to translate into
clinical studies. Lessons from the ongoing exosome-based prelim-
inary clinical trials in the field of cancer would certainly boost
such therapeutic perspectives. Particularly, one challenge would
be to control the fragile balance between the harmful effects and
beneficial ones reported for EVs in the context of cardiovascu-
lar diseases. However, cardiovascular field would undoubtedly
benefit from optimized developed methods for large-scale pro-
duction of clinical grade EVs derived from MSC (27) or dendritic
cells (86).
By inhibiting their deleterious effects, by taking advantage of
their regenerative properties or by developing EV-based drug-
delivery tools, targeting EVs reveal all the exciting opportu-
nities to treat cardiovascular alterations by non-immunogenic
means. In particular, EVs carrying Shh+ represent interesting
tools to treat diseases related to failed NO pathway and impaired
angiogenesis.
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